Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Multiple myeloma / Plasma cell neoplasm
Stage/Subtype:  extramedullary plasmacytoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 29 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Busulfan, Fludarabine Phosphate, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: HEM-05011-L, NCI-2013-00779, CDR0000447204, OHSU-210, OHSU-HEM-05011-L, NCT00245037
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, NCT00968630
Rasburicase or Allopurinol in Preventing Tumor Lysis Syndrome in Patients with Hematological Malignancies Undergoing Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2010-0284, NCI-2012-01889, NCI-2010-02082, NCT01200485
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11D.247, NCI-2011-02345, 1795, 2011-31, NCT01384513
Fludarabine Phosphate, Melphalan, and Total-Body Irradiation before Donor Double Umbilical Cord Blood Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 11-085, NCI-2012-00147, NCT01408563
Bulk or Fractionated Stem Cell Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: Under 75
Trial IDs: 12-016, NCI-2012-00824, NCT01596257
Autologous Stem Cell Transplant Followed by Maintenance Therapy in Treating Elderly Patients with Multiple Myeloma
Phase: Phase II
Type: Treatment
Age: 65 to 85
Trial IDs: 201208775, NCI-2013-00883, 10120146, NCT01849783
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378AUS23, NCI-2014-02128, NCT02186821
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TG02-101, NCI-2010-02048, NCT01204164
Sirolimus or Vorinostat in Combination with Hydroxychloroquine in Treating Patients with Advanced or Metastatic Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0588, NCI-2011-00303, NCT01266057
Pazopanib Hydrochloride and Vorinostat in Treating Patients with Advanced Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0051, NCI-2011-00771, NCT01339871
Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA209-039, NCI-2012-02776, NCT01592370
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SNX-5422-CLN1-005, NCI-2014-00715, NCT01635712
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EPZ-5676-12-001, NCI-2012-02880, NCT01684150
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TGR-1202-101 (HEMREF 31), NCI-2013-01694, TGR-1202-101, NCT01767766
Ipilimumab in Treating Patients with Relapsed Hematologic Malignancies after Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-537, NCI-2013-00739, 9204, NCT01822509
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CFZ002, NCI-2013-01934, NCT01949545
Start Over